Genomics and phenomics of body mass index reveals a complex disease network
- PMID: 36581621
- PMCID: PMC9798356
- DOI: 10.1038/s41467-022-35553-2
Genomics and phenomics of body mass index reveals a complex disease network
Abstract
Elevated body mass index (BMI) is heritable and associated with many health conditions that impact morbidity and mortality. The study of the genetic association of BMI across a broad range of common disease conditions offers the opportunity to extend current knowledge regarding the breadth and depth of adiposity-related diseases. We identify 906 (364 novel) and 41 (6 novel) genome-wide significant loci for BMI among participants of European (N~1.1 million) and African (N~100,000) ancestry, respectively. Using a BMI genetic risk score including 2446 variants, 316 diagnoses are associated in the Million Veteran Program, with 96.5% showing increased risk. A co-morbidity network analysis reveals seven disease communities containing multiple interconnected diseases associated with BMI as well as extensive connections across communities. Mendelian randomization analysis confirms numerous phenotypes across a breadth of organ systems, including conditions of the circulatory (heart failure, ischemic heart disease, atrial fibrillation), genitourinary (chronic renal failure), respiratory (respiratory failure, asthma), musculoskeletal and dermatologic systems that are deeply interconnected within and across the disease communities. This work shows that the complex genetic architecture of BMI associates with a broad range of major health conditions, supporting the need for comprehensive approaches to prevent and treat obesity.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
C.J.O’D. is employed by Novartis Institutes for Biomedical Research. P.D.R. has received research grant support from the following for-profit companies: Bristol Myers Squib, Lysulin Inc; and has consulted with Intercept Pharmaceuticals and Boston Heart Diagnostics. D.S. has received support from the British Heart Foundation, Pfizer, Regeneron, Genentech, and Eli Lilly pharmaceuticals. L.S.P. declares that there is no duality of interest associated with this manuscript. With regard to potential conflicts of interest, L.S.P. has served on Scientific Advisory Boards for Boehringer Ingelheim and Janssen, and has or had research support from Merck, Pfizer, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, Abbvie, Vascular Pharmaceuticals, Janssen, Glaxo SmithKline, and the Cystic Fibrosis Foundation. L.S.P. is also a cofounder and Officer and Board member and stockholder of a company, Diasyst, Inc., which markets software aimed to help improve diabetes management. S.M.D receives research support from Renalytix AI and Novo Nordisk to the University of Pennsylvania and consulting fees from Calico Labs. A.-L.B. is co-scientific founder of and is supported by Scipher Medicine, Inc. G.D.S. is a member of the Scientific Advisory Boards of Relation Therapeutics and Insitro. The remaining authors declare no competing interests.
Figures


Similar articles
-
A data-driven approach for studying the role of body mass in multiple diseases: a phenome-wide registry-based case-control study in the UK Biobank.Lancet Digit Health. 2019 Jul;1(3):e116-e126. doi: 10.1016/S2589-7500(19)30028-7. Epub 2019 Jun 27. Lancet Digit Health. 2019. PMID: 33323262
-
Quantifying the phenome-wide disease burden of obesity using electronic health records and genomics.Obesity (Silver Spring). 2022 Dec;30(12):2477-2488. doi: 10.1002/oby.23561. Epub 2022 Nov 13. Obesity (Silver Spring). 2022. PMID: 36372681 Free PMC article.
-
A Phenome-Wide Mendelian Randomization Study of Pancreatic Cancer Using Summary Genetic Data.Cancer Epidemiol Biomarkers Prev. 2019 Dec;28(12):2070-2078. doi: 10.1158/1055-9965.EPI-19-0036. Epub 2019 Jul 17. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 31315910
-
Causal role of high body mass index in multiple chronic diseases: a systematic review and meta-analysis of Mendelian randomization studies.BMC Med. 2021 Dec 15;19(1):320. doi: 10.1186/s12916-021-02188-x. BMC Med. 2021. PMID: 34906131 Free PMC article.
-
Health effects of high serum calcium levels: Updated phenome-wide Mendelian randomisation investigation and review of Mendelian randomisation studies.EBioMedicine. 2022 Feb;76:103865. doi: 10.1016/j.ebiom.2022.103865. Epub 2022 Feb 6. EBioMedicine. 2022. PMID: 35134646 Free PMC article.
Cited by
-
Integration of expression QTLs with fine mapping via SuSiE.PLoS Genet. 2024 Jan 25;20(1):e1010929. doi: 10.1371/journal.pgen.1010929. eCollection 2024 Jan. PLoS Genet. 2024. PMID: 38271473 Free PMC article.
-
Integrating Genetic and Transcriptomic Data to Identify Genes Underlying Obesity Risk Loci.medRxiv [Preprint]. 2024 Jun 12:2024.06.11.24308730. doi: 10.1101/2024.06.11.24308730. medRxiv. 2024. PMID: 38903089 Free PMC article. Preprint.
-
Defective FGFR1 Signaling Disrupts Glucose Regulation: Evidence From Humans With FGFR1 Mutations.J Endocr Soc. 2024 Jun 13;8(8):bvae118. doi: 10.1210/jendso/bvae118. eCollection 2024 Jul 1. J Endocr Soc. 2024. PMID: 38957656 Free PMC article.
-
Bayesian network imputation methods applied to multi-omics data identify putative causal relationships in a type 2 diabetes dataset containing incomplete data: An IMI DIRECT Study.PLoS Genet. 2025 Jul 15;21(7):e1011776. doi: 10.1371/journal.pgen.1011776. eCollection 2025 Jul. PLoS Genet. 2025. PMID: 40663565 Free PMC article.
-
Integration of bulk and single-cell RNA-seq reveals prognostic gene signatures in patients with bladder cancer treated with immune checkpoint inhibitors.Cancer Immunol Immunother. 2024 Dec 21;74(1):28. doi: 10.1007/s00262-024-03839-7. Cancer Immunol Immunother. 2024. PMID: 39708127 Free PMC article.
References
-
- Syn NL, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet. 2021;397:1830–1841. doi: 10.1016/S0140-6736(21)00591-2. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
- UM1 DK126194/DK/NIDDK NIH HHS/United States
- R01 DK110113/DK/NIDDK NIH HHS/United States
- R01 DK075787/DK/NIDDK NIH HHS/United States
- R01 DK101478/DK/NIDDK NIH HHS/United States
- I01 BX003340/BX/BLRD VA/United States
- I01 CX001737/CX/CSRD VA/United States
- I01 BX003362/BX/BLRD VA/United States
- I01 BX005831/BX/BLRD VA/United States
- P01 HL132825/HL/NHLBI NIH HHS/United States
- I01 BX004821/BX/BLRD VA/United States
- R01 NR013520/NR/NINR NIH HHS/United States
- MC_UU_00011/1/MRC_/Medical Research Council/United Kingdom
- R01 DK107786/DK/NIDDK NIH HHS/United States
- IK2 CX001907/CX/CSRD VA/United States
- IK2 CX001780/CX/CSRD VA/United States
LinkOut - more resources
Full Text Sources